科济药业-B(02171)发布公告，于2025年11月11日斥资404.73万港元回购24.5万股股份。 ...

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Company Summary - Kintor Pharmaceutical plans to repurchase 245,000 shares at a total cost of HKD 4.0473 million [1]

格隆汇11月11日丨科济药业-B(02171.HK)公告，11月11日耗资404.7万港元回购24.5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kexing Pharmaceutical-B (02171) by purchasing 30,000 shares at a price of HKD 16.4 per share, totaling HKD 492,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 30,000 shares at a price of HKD 16.4 each, amounting to a total investment of HKD 492,000 [1] - **Post-Purchase Holdings** - Following the purchase, Guo Huaqing's total shareholding in Kexing Pharmaceutical-B increased to approximately 218 million shares, representing a 37.73% ownership stake [1]

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (02171) by purchasing 30,000 shares at a price of HKD 16.4 per share, totaling HKD 492,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Shareholding Activity** - Guo Huaqing's recent purchase brings his total shareholding to approximately 218 million shares, representing a 37.73% ownership stake in Kintor Pharmaceutical [1]

本报讯(记者陈潇)11月6日，国际指数编制公司明晟(MSCI)公布2025年11月份指数审议结果，调整将于 11月24日收盘后正式生效。本次调整中，MSCI全球小盘股指数新增22只个股，科济药业控股有限公司 (以下简称"科济药业-B"，股票代码：2171.HK)成功入选。 此次公司获纳入MSCI全球小盘股指数，有望使科济药业-B获得更多全球资金关注，进一步提升股票流 动性及市场估值水平。 此前，科济药业-B已被纳入MSCI香港小型股指数，本次调整系其由香港地区指数纳入中国地区指数。 据悉，MSCI指数受到全球机构投资者的广泛追踪和参考，指数调整主要依据市值、流动性等客观量化 指标，个股纳入通常被视为获得全球资本市场认可的信号，有望吸引被动资金配置，为相关上市公司带 来流动性提升机遇。 作为中国生物医药CGT领域的领军企业，科济药业不断致力于在治疗血液恶性肿瘤和实体瘤的创新 CAR-T细胞疗法上实现新突破。近期，科济药业董事长李宗海在采访中表示，科济药业始终围绕CAR-T 赛道的关键挑战做创新，一是攻克难治肿瘤，二是降低治疗成本，让更多老百姓用得起。 ...

Summary of Key Points Core Viewpoint - On November 7, 43 Hong Kong-listed companies conducted share buybacks, totaling 24.24 million shares and an aggregate amount of HKD 163 million [1]. Group 1: Buyback Details - China Feihe repurchased 6 million shares for HKD 26.08 million, with a highest price of HKD 4.360 and a lowest price of HKD 4.340, bringing its total buyback amount for the year to HKD 310.46 million [1][2]. - COSCO Shipping Holdings repurchased 1.408 million shares for HKD 19.86 million, with a highest price of HKD 14.230 and a lowest price of HKD 13.800, accumulating a total buyback amount of HKD 4.678 billion for the year [1][2]. - Kintor Pharmaceutical repurchased 876,500 shares for HKD 13.78 million, with a highest price of HKD 16.000 and a lowest price of HKD 15.180, totaling HKD 47.76 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on November 7 was from China Feihe at HKD 26.08 million, followed by COSCO Shipping Holdings at HKD 19.86 million [1][2]. - In terms of share quantity, China Feihe led with 6 million shares repurchased, followed by China Petroleum & Chemical Corporation with 3.172 million shares and Linklogis Technology with 2.39 million shares [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include China Petroleum & Chemical Corporation, AAC Technologies, and Kintor Pharmaceutical, with respective buyback amounts of HKD 13.57 million, HKD 11.70 million, and HKD 7.49 million [2][3]. - The buyback activities reflect a trend among Hong Kong-listed companies to utilize excess cash for shareholder returns, indicating confidence in their financial health [1][2].

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.11.07 | 87.65 | 16.000 | 15.180 | 1377.93 | | 2025.11.06 | 173.40 | 15.800 | 14.350 | 2630.78 | | 2025.10.23 | 20.50 | 16.700 | 16.470 | 339.82 | | 2025.10.21 | 25.00 | 17.150 | 16.990 | 426.98 | 自11月6日以来公司已连续2日进行回购，合计回购261.05万股，累计回购金额4008.71万港元。 其间该 股累计上涨1.02%。 今年以来该股累计进行4次回购，合计回购306.55万股，累计回购金额4775.51万港元。（数据宝） 科济药业-B回购明细 证券时报·数据宝统计，科济药业-B在港交所公告显示，11月7日以每股15.180港元至16.000港元的价格 回购87.65万股，回购金额达1377.93万港元。该股当日收盘价15.790 ...

Core Viewpoint - 科济药业-B (02171.HK) announced a share buyback of 876,500 shares at a cost of HKD 13.78 million on November 7 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 13.78 million, reflecting a strategic move to enhance shareholder value [1] - The number of shares repurchased was 876,500, which may impact the company's share structure and market perception [1]